CA2708719A1 - High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles - Google Patents

High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles Download PDF

Info

Publication number
CA2708719A1
CA2708719A1 CA2708719A CA2708719A CA2708719A1 CA 2708719 A1 CA2708719 A1 CA 2708719A1 CA 2708719 A CA2708719 A CA 2708719A CA 2708719 A CA2708719 A CA 2708719A CA 2708719 A1 CA2708719 A1 CA 2708719A1
Authority
CA
Canada
Prior art keywords
peptide
lipid
nanoscaffold
hpps
lipid nanoscaffold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2708719A
Other languages
English (en)
French (fr)
Inventor
Gang Zheng
Zhihong Zhang
Ian Corbin
Juan Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2708719A1 publication Critical patent/CA2708719A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
CA2708719A 2007-12-12 2008-12-12 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles Abandoned CA2708719A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1323307P 2007-12-12 2007-12-12
US61/013,233 2007-12-12
US10450608P 2008-10-10 2008-10-10
US61/104,506 2008-10-10
PCT/CA2008/002203 WO2009073984A1 (en) 2007-12-12 2008-12-12 High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles

Publications (1)

Publication Number Publication Date
CA2708719A1 true CA2708719A1 (en) 2009-06-18

Family

ID=40755223

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2708719A Abandoned CA2708719A1 (en) 2007-12-12 2008-12-12 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles

Country Status (6)

Country Link
US (1) US20110020242A1 (enExample)
EP (1) EP2229411B1 (enExample)
JP (1) JP5658568B2 (enExample)
CN (2) CN102027019A (enExample)
CA (1) CA2708719A1 (enExample)
WO (1) WO2009073984A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230711A1 (en) * 2022-05-31 2023-12-07 University Health Network Lipid nanoparticle for the delivery of rna

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011035279A2 (en) * 2009-09-21 2011-03-24 Board Of Regents, The University Of Texas System Nanocarriers for imaging and therapy applications
US10498796B2 (en) * 2009-10-16 2019-12-03 Real Innovations International Llc System and method for providing real-time data
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
KR101405403B1 (ko) * 2010-01-20 2014-06-11 주식회사 진코스 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
CA2883080A1 (en) * 2011-08-26 2013-03-07 Vecoy Nanomedicines Ltd. Pathogen and substance traps
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
CA2865279C (en) * 2012-02-22 2023-04-25 Northwestern University Nanostructures for treating cancers and other conditions
JP2014129317A (ja) * 2012-02-23 2014-07-10 Canon Inc 光音響造影剤用色素含有ナノ粒子
CN102766215B (zh) 2012-06-07 2014-08-13 华中科技大学 一种具有协同靶向诊疗鼻咽癌功能的多肽和携带此多肽的纳米颗粒及其应用
EP2882459A1 (en) 2012-08-10 2015-06-17 University of North Texas Health Science Center Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
WO2015013673A1 (en) 2013-07-25 2015-01-29 Aurasense Therapeutics, Llc Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
JP6692748B2 (ja) 2013-09-26 2020-05-13 ナショナル ユニヴァーシティー オブ シンガポール リゾホスファチジルコリンの足場を利用する組成物及び方法
MX389323B (es) 2013-12-03 2025-03-20 Univ Northwestern Particulas liposomales, metodos para elaborarlas y sus usos.
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2015192215A1 (en) * 2014-06-20 2015-12-23 University Health Network Peptide containing porphyrin lipid nanovesicles
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
JP6741673B2 (ja) 2014-10-06 2020-08-19 イグジキュア, インコーポレーテッドExicure, Inc. 抗ｔｎｆ化合物
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016085986A1 (en) 2014-11-24 2016-06-02 Northwestern University High density lipoprptein nanoparticles for inflammation
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
DK3319980T3 (da) 2015-07-10 2021-11-22 Peptinovo Biopharma Inc Formuleringer til forbedring af virkningen af hydrofobe lægemidler
CN106831997B (zh) * 2015-12-03 2020-04-24 中国科学院苏州纳米技术与纳米仿生研究所 多肽、脂蛋白样纳米粒子及其应用
HK1257429A1 (zh) 2016-02-04 2019-10-18 ALASTIN Skincare, Inc. 用於侵入性和非侵入性程序性护肤的组合物和方法
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
KR102617833B1 (ko) 2016-05-06 2023-12-27 엑시큐어 오퍼레이팅 컴퍼니 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
EP3595684A1 (en) * 2017-03-17 2020-01-22 Senti Biosciences, Inc. Immunomodulating cell circuits
SG10202111394XA (en) 2017-04-13 2021-12-30 Senti Biosciences Inc Combinatorial cancer immunotherapy
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
KR20200028997A (ko) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 올리고뉴클레오타이드-작용화된 금속-유기 프레임워크 나노입자를 제조하는 일반적이고 직접적인 방법
KR102757675B1 (ko) 2017-08-03 2025-01-20 앨러스틴 스킨케어, 인크. 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법
CN107573418B (zh) * 2017-08-21 2020-09-25 华中科技大学 肿瘤相关巨噬细胞双靶向多肽、纳米颗粒、制备及应用
CA3082830A1 (en) * 2017-11-21 2019-05-31 Icahn School Of Medicine At Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
CN108143719B (zh) * 2017-12-27 2022-01-25 华中科技大学 一种携载多肽的纳米脂质体及其制备方法和应用
WO2019133914A1 (en) * 2017-12-29 2019-07-04 Wayne State University Method of treatment for solid tumors containing hypoxia and/or stroma features
CN108685875B (zh) * 2018-07-30 2020-11-03 中国药科大学 一种抗阿尔兹海默症的天然纳米粒-药物组合物及其制备方法和应用
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
CN110123761B (zh) * 2019-05-07 2022-09-06 沈阳药科大学 一种仿生型高密度脂蛋白纳米粒及其制备和应用
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN111012555A (zh) * 2019-12-03 2020-04-17 刘训伟 载放射性核素微纳米涂层支架及其制备方法
CN111150834A (zh) * 2020-01-06 2020-05-15 吉林大学 一种载脂蛋白e与盐霉素复合纳米粒及制备方法和应用
CN111494641B (zh) * 2020-04-22 2021-08-03 南开大学 肿瘤微环境响应性的表面电荷可反转纳米药物递送载体
CA3199462A1 (en) * 2020-10-23 2022-04-28 Northwestern University Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles
CN117355298A (zh) 2021-03-19 2024-01-05 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
WO2022231724A1 (en) * 2021-04-28 2022-11-03 The Regents Of The University Of California Adipocyte-derived anti-cancer lipid droplets
JP2024526343A (ja) * 2021-07-13 2024-07-17 ユニバーシティー ヘルス ネットワーク 脂肪酸抱合体を有するポルフィリンナノ小胞
CN116602923A (zh) * 2023-07-20 2023-08-18 暨南大学附属第一医院（广州华侨医院） 一种用于关节炎治疗的靶向仿生纳米治疗载体系统

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166214A (en) * 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
JPH07501540A (ja) 1991-11-25 1995-02-16 リチャードソン、ビックス、インコーポレーテッド 皮膚シワ及び／又は皮膚萎縮を調節するための組成物
DE69725714T2 (de) 1996-04-23 2004-07-29 The Procter & Gamble Company, Cincinnati Verfahren und regelung des hautaussehens mit vitamin - b3 - verbindungen
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20040234588A1 (en) * 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
KR101186210B1 (ko) * 2002-12-03 2012-10-08 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 혈뇌장벽을 통과하는 물질 수송용 인공 저밀도 지단백질 운반체
US8097283B2 (en) * 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
EP1778298A4 (en) * 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US8101741B2 (en) * 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
WO2007145659A1 (en) * 2005-11-10 2007-12-21 The Regents Of The University Of California Synthetic ldl as targeted drug delivery vehicle

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023230711A1 (en) * 2022-05-31 2023-12-07 University Health Network Lipid nanoparticle for the delivery of rna

Also Published As

Publication number Publication date
EP2229411A1 (en) 2010-09-22
CN102027019A (zh) 2011-04-20
CN105903029A (zh) 2016-08-31
JP5658568B2 (ja) 2015-01-28
US20110020242A1 (en) 2011-01-27
JP2011507807A (ja) 2011-03-10
EP2229411B1 (en) 2019-02-27
EP2229411A4 (en) 2015-03-04
WO2009073984A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
EP2229411B1 (en) High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
Wang et al. Strategies for liposome drug delivery systems to improve tumor treatment efficacy
Jiang et al. Mitochondrion-specific dendritic lipopeptide liposomes for targeted sub-cellular delivery
US20080253960A1 (en) Lipoprotein-Based Nanoplatforms
Meng et al. Quantitative assessment of nanoparticle biodistribution by fluorescence imaging, revisited
US8361494B2 (en) Biomimetic iron-oxide-containing lipoprotein and related materials
Lainé et al. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring
Singh et al. RGD-TPGS decorated theranostic liposomes for brain targeted delivery
Song et al. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects
Shao et al. A smart multifunctional nanoparticle for enhanced near-infrared image-guided photothermal therapy against gastric cancer
Lu et al. Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII
Ding et al. Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy
Liu et al. Biomimetic human serum albumin nanoparticle for efficiently targeting therapy to metastatic breast cancers
Dattani et al. A comparative study on micelles, liposomes and solid lipid nanoparticles for paclitaxel delivery
Zhang et al. Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
Wang et al. MMP-2-controlled transforming micelles for heterogeneic targeting and programmable cancer therapy
Valetti et al. Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice
Charron et al. Theranostic lipid nanoparticles for cancer medicine
Corbin et al. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers
Aryasomayajula et al. Multifunctional liposomes
Li et al. iRGD peptide-mediated liposomal nanoparticles with photoacoustic/ultrasound dual-modality imaging for precision theranostics against hepatocellular carcinoma
Liu et al. Cyclic RGD-decorated liposomal gossypol AT-101 targeting for enhanced antitumor effect
Tian et al. Understanding the cellular uptake and biodistribution of a dual-targeting carrier based on redox-sensitive hyaluronic acid-ss-curcumin micelles for treating brain glioma
Lee et al. Functionalized, long-circulating, and ultrasmall gold nanocarriers for overcoming the barriers of low nanoparticle delivery efficiency and poor tumor penetration
Tang et al. Estrone-conjugated pegylated liposome co-loaded paclitaxel and carboplatin improve anti-tumor efficacy in ovarian cancer and reduce acute toxicity of chemo-drugs

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131206

FZDE Discontinued

Effective date: 20191210